<DOC>
	<DOCNO>NCT02230618</DOCNO>
	<brief_summary>This study conduct Asia . The aim study evaluate long term safety efficacy patient diabetes mellitus routine clinical practice India .</brief_summary>
	<brief_title>Post Marketing Surveillance ( PMS ) Study Ryzodeg™ ( Insulin Degludec /Insulin Aspart ) Patients With Diabetes Mellitus Routine Clinical Practice India</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . ( Studyrelated activity procedure relate record data accord protocol ) . The historical data include data inform consent obtain ( e.g. , HbA1c ( Glycated Haemoglobin ) , FPG ( Fasting Plasma Glucose ) , PPPG ( Postprandial Plasma Glucose ) , severe hypoglycaemia start Ryzodeg™ therapy ) use baseline data Patients insulin require diabetes mellitus schedule start treatment Ryzodeg™ base clinical judgment treat physician Known suspect allergy Ryzodeg™ active substance excipients Previous participation study Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Patients previously Ryzodeg™ therapy Patients participate study clinical trial Patients pregnant , breast feeding intention become pregnant within follow 12 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>